^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    imatinib

    i
    Other names: CGP 57148, CTI 571, STI 571, QTI 571, CTI1571, STI571, CGP 57148B, STI-571, QTI571
    Company:
    Generic mfg.
    Drug class:
    c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor
    Related drugs:
    9ms
    - CML imatinib (& other rarer dz) - EGFR, ALK, ROS, & others in NSCLC - HER2 in breast, gastric Ca - BRAF/MEK in melanoma, thyroid & others - FLT3, IDH in AML (tho trial designs variable) - PSMA in Lu-PSMA @Dr_R_Kurzrock (@Eddie_Cliff)
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    imatinib
    10ms
    1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    gefitinib • imatinib
    10ms
    Not true, when Mark’s company first started he always talked about a leukemia drugs for kids called Imatinib that’s available through the pharmacy. It’s a chemotherapy. Its retail value at the time was like $2500 and available through this company for $20 (@David97903896)
    imatinib
    10ms
    They have Imatinib, a leukemia chemotherapy. Not sure why they wouldn’t carry others (@David97903896)
    imatinib
    11ms
    Elias Jabbour: Presented PhALLCON study data, higher MRD neg CR with ponatinib. Better PFS, no difference in OS (albeit shorter fu, cross over; imatinib pt receiving 2/3rd generation TKI on relapse). G3/4 AEs were comparable. #EHA2023 #EHA23 #leusm (@TalhaBadarMD)
    imatinib • Iclusig (ponatinib)
    11ms
    Elias Jabbour: Presented PhALLCON study data, higher MRD neg CR with ponatinib. Better PFS, no difference in OS (albeit shorter fu and imatinib pt receiving 2/3rd generation TKI on relapse). G3/4 AEs were comparable. #EHA2023 #EHA23 #leusm (@TalhaBadarMD)
    imatinib • Iclusig (ponatinib)
    11ms
    HOPES in Gist. Si somos capaces de detectar mutaciones de resistencia a imatinib y desarrollar farmacos dirigidos que las reviertan podremos impactar en la supervivencia de los pacientes. #GIST @DrCeSarcoma @colectivogist (@GrupoGeis)
    imatinib
    11ms
    A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia https://t.co/0MJllt15hd #CML #scRNAseq @BloodJournal (@TalhaBadarMD)
    imatinib
    11ms
    https://t.co/1taZrhA1gA: Treatment failure with first line imatinib for patients with chronic myeloid leukaemia in Kenya vs high-income countries. ➡️ Imatinib failure rate 15% #ASCO23 (@TalhaBadarMD)
    Clinical
    |
    imatinib
    11ms
    PHALLCON: A PHASE 3 STUDY COMPARING PONATINIB VERSUS IMATINIB IN NEWLY DIAGNOSED PH+ ALL .... by Dr. Elias Jabbour EHA Library; Jun 08 2023; 387810 https://t.co/OH6yo7ci3P #ALL #EHA23 (@smbenlazar)
    imatinib • Iclusig (ponatinib)
    11ms
    PHALLCON study: Ponatanib vs imatinib with low intensity chemotherapy in Ph positive ALL: significantly better molecular MRD -ve CR with ponatinib and trends towards better EFS. #EHA23 #leusm (@TalhaBadarMD)
    Minimal residual disease
    |
    imatinib • Iclusig (ponatinib)
    12ms
    •KIT/PDGFRA mutations in metastatic, imatinib-resistant #GIST •Prior Tx selects for resistant A-loop mutations •ctDNA resistance mutations prognosticate efficacy of 3rd/4th-line TKI @Annals_Oncology @DrCeSarcoma @SteveBialickDO @seppobauer S. George https://t.co/Mgzutsu317 (@JTrentMDPhD)
    Clinical • Circulating tumor DNA • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation
    |
    imatinib
    12ms
    📰in Annals of Oncology, investigators studied the landscape of KIT & PDGFRA mutations in metastatic, imatinib-resistant GIST using ctDNA sequencing 🩸🧪🧬 on pre and post-treatment plasma samples in the VOYAGER clinical trial https://t.co/6y16OZsbyt @JTrentMDPhD @DrCeSarcoma (@Annals_Oncology)
    Clinical • Circulating tumor DNA • Metastases
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA mutation
    |
    imatinib
    1year
    KIT And PDGFRA Mutations And Survival of Gastrointestinal Stromal Tumor Patients Treated With Adjuvant Imatinib in a Randomized Trial https://t.co/3dxDyIp0ei (@PestanaRC)
    Clinical • Stroma
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA mutation
    |
    imatinib
    1year
    Adjuvant Imatinib for resected high-risk GIST Does it only postpone/delay relapse? Optimal duration? 3 yrs/ 5 yrs / Indefinite? These curves resemble adjuvant EGFR-TKI for resected NSCLC- ADAURA anyone? @RashidLui @OncBrothers @JackWestMD @VanitaNoronha @SuyogCancer (@shikharkumar89)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    imatinib
    1year
    37/F, De Novo AML with FIP1L1-PDGFRa mutation, post 7+3 in CR. Should we continue low dose Imatinib maintenance with FIP1L1-PDGFRa PCR monitoring or go for upfront alloSCT? (10/10 MUD available.) Need your expertise @nihardesai7 @AaronGoodman33 @SujayRainchwar @NutanJoshi27 (@DigambarPanchal)
    Clinical
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1)
    |
    PDGFRA mutation
    |
    imatinib
    1year
    Probably this is transformed AML from Eosinophilia. Just need to check if the NGS shows PDGFRA D842V mutation. If this mutation present , then it won’t respond to imatinib. Avapritinib is drug of choice. We had similar patient whom we transplanted in CR1. Relapsed with EM disez. (@SujayRainchwar)
    Clinical • Next-generation sequencing
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    PDGFRA D842V • PDGFRA mutation
    |
    imatinib • Ayvakit (avapritinib)
    1year
    50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib
    over1year
    #ASH22 #leusm “CML with additional genetic abnormalities (ASXL1m)” ➡️ Associated with inf molecular resp in Imatinib Rx pts. ⬆️ However, outcome was better with 2nd generation TKI! https://t.co/8vXIVRf0Zw (@TalhaBadarMD)
    Clinical
    |
    ASXL1 (ASXL Transcriptional Regulator 1)
    |
    imatinib
    over1year
    Six riddles for precision oncology Riddle #3: do mutations possess tissue tropism? Yes and no B-RAF V600E is everywhere— melanoma, hairy cell leukemia, lung Ca, etc Bcr-Abl is leukemia— but wait— GBM case (imatinib response): brain tumor didn’t read the books Need universal NGS! (@Dr_R_Kurzrock)
    Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BRAF V600E • BRAF V600
    |
    imatinib
    over1year
    Clonal eosinophilia FIP1L1-PDGFRA= CHIC2 del= imatinib 100 ETV6-PDGFRB = t(5;12)= imatinib 400 ZMYM2-FGFR1= t(8;13)= TKI+AML/ALL induction+allo PCM1-JAK2= t(8;9)= ruxolitinib+allo ETV6-FLT3/ABL1= t(12;13)/t(9;12)= dasatinib+allo Lymphocytic= T-cell clone makes IL5= mepolizumab (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • PCM1 (Pericentriolar Material 1) • IL5 (Interleukin 5)
    |
    dasatinib • imatinib • Jakafi (ruxolitinib)
    over1year
    50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib
    almost2years
    #ASCO22 #leusm Menghrajani: Why aren’t JAKi the new imatinib in JAK2 mutated MPN? JAK-STAT may not be only pathway involved. Adding BCL2i to Rux shows promising results. (@hemedoc)
    JAK2 (Janus kinase 2)
    |
    JAK2 mutation
    |
    imatinib
    almost2years
    Clonal eosinophilia! FIP1L1-PDGFRA= CHIC2 del= imatinib 100 ETV6-PDGFRB = t(5;12)= imatinib 400 ZMYM2-FGFR1= t(8;13)= TKI+AML/ALL induction+allo PCM1-JAK2= t(8;9)= ruxolitinib+allo ETV6-FLT3/ABL1= t(12;13)/t(9;12)= dasatinib+allo Lymphocytic= T-cell clone makes IL5= mepolizumab (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • FGFR1 (Fibroblast growth factor receptor 1) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • ETV6 (ETS Variant Transcription Factor 6) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1) • PCM1 (Pericentriolar Material 1) • IL5 (Interleukin 5)
    |
    dasatinib • imatinib • Jakafi (ruxolitinib)
    almost2years
    We evaluated Fibroblast Growth Factor Receptor inhibitors in our xenograft models of gastrointestinal stromal tumor. Some efficacy, unlikely a game changer, and again no added value when combining with imatinib. See Schöffski et al., doi: 10.3390/biomedicines10051135 (@schoffski)
    Preclinical
    |
    FGFR (Fibroblast Growth Factor Receptor)
    |
    imatinib
    almost2years
    Progress! After BCR-ABL1 that was detected but not enough to quantify my hematologist agreed to reduce my nightly dosage of #imatinib to 200 mg. I pray it works. #cml @CMLSupportGroup @cmlnet @LLSusa #Cancersucks (@espwapouJacmel)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib
    2years
    HPI: 50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib
    2years
    👍 The combination of imatinib and binimetinib is effective w/ manageable toxicity in frontline treatment of #GastrointestinalStromalTumor ➡️ https://t.co/Fosnp4H7SX @WTapMD #GIST #JCO #scmsm (@JCO_ASCO)
    WTAP (WT1 Associated Protein)
    |
    imatinib • Mektovi (binimetinib)
    2years
    CML That is not Typical CML: MPN 100% BCR-ABL+ ⬇️dysplasia Basophilia Chronic->blast (AML or ALL) Rx = Imatinib aTypical CML: MPN/MDS overlap 100% BCR-ABL neg SETBP1,ASXL1,N/K-RAS,SRSF2 Dysplasia Neutrophilia 🚫basophilia AML blast phase Rx = HMA, Hydrea, allo ASH Image Bank (@AaronGoodman33)
    KRAS (KRAS proto-oncogene GTPase) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • SETBP1 (SET Binding Protein 1)
    |
    imatinib • hydroxyurea
    2years
    KIT+ MEK inhibition in GIST ➡️Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor ⭐️The best ORR was 69.0% @WTapMD @JTrentMDPhD @JCO_ASCO https://t.co/4EKyGH0TsZ (@VivekSubbiah)
    Clinical
    |
    WTAP (WT1 Associated Protein)
    |
    imatinib • Mektovi (binimetinib)
    over2years
    50 yo asymptomatic with neutrophilic leukocytosis, basophilia, splenomegaly Smear with leukocytosis rare blasts, myelocytes, sets, mature PMNs, basophils. Note WBCs many different shapes and sizes unlike acute leukemia (blasts all big). = CML = t(9;22) =BCR-ABL1 Rx imatinib (@AaronGoodman33)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    imatinib
    over2years
    Malignant Neutrophilia! @doctorpemm Chronic neutrophilic leukemia Neutrophilia no dysplasia CSF3R mut Rx = Ruxolitnib->allo aCML BCR-ABL - Neutrophilia+dysplasia STBP1/ASXL1 Rx = HMA->allo CML BCR-ABL+ (p230!) Rx = imatinib Myeloma with neutrophilia Paraneoplastic⬆️GCSF (@AaronGoodman33)
    ASXL1 (ASXL Transcriptional Regulator 1) • CSF3R (Colony Stimulating Factor 3 Receptor)
    |
    imatinib
    almost3years
    Congrats to @DocCatenacci and colleagues for this landmark study! FGF has been a target of research since imatinib without success but now bringing it home for 30% of #gastric #cancer with +IHC for FGFR2. Marker dependent major ⬆️ increases in OS❗️trials @RutgersCancer (@HH_Oncodr)
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    imatinib
    3years
    - Aspirin for pain relief/fever reduction; - Ibuprofen for pain relief; - Imatinib for CML; - Trastuzumab for HER2* breast cancer; - ART for HIV; - Thiazide diuretics/beta blockers/blood thinners for cardiovascular disease (@JoshuaPCohen1)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • imatinib • aspirin
    over3years
    #ASH20 #leusm Sasaki: IKZF1 deletions known to be risk for poor outcome in Ph+ ALL treated with imatinib or dasatinib. Pre-tx samples from 55 tx with hCVAD/Dasat and 50 tx with hCVAD/Ponat evaluated. IZKF1del found in 60%. (@hemedoc)
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    IKZF1 deletion
    |
    dasatinib • imatinib
    almost4years
    NET not GIST. Only case reports of Glivec working in NETs with KIT mutations. (@SiBucz)
    Clinical
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation
    |
    imatinib
    almost4years
    CTONG 1104 with gefitinib is not proof that osi lacks activity in adjuvant setting in lung cancer by any means, that’s why ADAURA data esp mature OS so important. But I am confused as to how imatinib in GIST is somehow a better analogy than CTONG1104, a trial in EGFR+ nsclc (@PatelOncology)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    gefitinib • imatinib
    4years
    Approval of imatinib almost 20 years ago heralded the arrival of the targeted therapy era in oncology and thrust the ABL1 kinase into the limelight #leukemia https://t.co/pDtfBGhb4L (@OncLive)
    ABL1 (ABL proto-oncogene 1) • APP (Amyloid Beta Precursor Protein)
    |
    imatinib